...companies completed their previously announced merger to form Kiadis Pharma B.V. (see BioCentury, Dec. 4). Celmed Biosciences Inc....

...Kiadis will acquire cancer company Celmed for an undisclosed amount of stock. Celmed's pipeline includes TH9402...
...its BioSelact screening technology to identify kinase inhibitors for cancer. Financial details were not disclosed. Celmed Biosciences Inc....

...Cancer and autoimmune company Celmed (Montreal, Quebec) promoted Mark Kaufmann to president and CEO from COO...
...VP of corporate development. He replaces Andre de Villers, who retired but will remain on Celmed's...

...as VP of corporate and business development, formerly VP of preclinical research and technologies at Celmed BioSciences Inc. WIR...

...TH's majority-owned subsidiary, Celmed BioSciences Inc. (Montreal, Quebec), completed its previously announced acquisition of cancer company NewBiotics (see...
...June 14). NewBiotics shareholders received a 29.7% ownership interest in Celmed, and TH's ownership in Celmed...

...TH's majority owned subsidiary, Celmed BioSciences Inc. (Montreal, Quebec), will acquire cancer company NewBiotics. NewBiotics shareholders will receive...
...shareholders will receive a 29.7% ownership interest in Celmed, which will reduce TH's ownership in Celmed...
...toxin by thymidylate synthase (TS) that is in Phase l/ll trials to treat colorectal cancer. Celmed...

...Theratechnologies (TSE:TH) subsidiary Celmed BioSciences will acquire cancer company NewBiotics (San Diego, Calif.) in a stock...
...NewBiotics shareholders will receive a 29.7% ownership interest in Celmed , which will reduce TH's Celmed...
...Last month, Celmed sold its neurology assets to Dr. Michel Levesque of Cedars Sinai Hospital. Celmed...

...sold the neurology assets of Celmed USA to Dr. Michel Levesque of Cedars Sinai Hospital. Celmed...